The battle against heart disease, a silent killer, is an ongoing war with significant progress and challenges. While it may not be as flashy as AI or gene editing, the recent FDA approval of enlicitide, a small pill, marks a quiet revolution in cardiovascular health. This pill, taken daily with a sip of coffee, water, or tea, achieves a remarkable 60% reduction in the most dangerous cholesterol type, rivaling injectable drugs.
What makes this development fascinating is its origin story. Two geneticists, Helen Hobbs and Jonathan Cohen, discovered a genetic mutation in a handful of individuals, mostly Black Americans, that efficiently cleared LDL cholesterol from the blood. This mutation, found in the PCSK9 gene, reduced heart disease risk by a staggering 88%. Drugmakers have since replicated this mutation, leading to enlicitide and other PCSK9 drugs.
Statins, the traditional cholesterol-lowering drugs, remain effective for many, but enlicitide offers an alternative for those intolerant to statins or unable to achieve sufficient LDL reduction. Additionally, gene editing techniques, like Verve Therapeutics' single-letter edit to the PCSK9 gene, may provide a permanent solution, eliminating the need for daily medication.
The decline in smoking rates and advancements in treating high blood pressure have also contributed to the fight against heart disease. Anti-obesity drugs, such as GLP-1s, are gaining popularity, with one trial showing a 20% reduction in cardiovascular events.
However, the war against heart disease is far from won. While enlicitide and similar drugs show promise, their impact on mortality rates remains to be seen. The widespread nature of heart disease means that treatments must be equally accessible and effective.
Heart disease is evolving, with a shift towards other heart conditions like heart failure and arrhythmias. Obesity, now affecting around 40% of US adults, is a growing concern, bringing with it diabetes and high blood pressure. Access to healthcare and medication remains a significant challenge, with many patients discontinuing statins within a year.
Enlicitide, a humble pill, represents the culmination of decades of scientific research, turning a deadly medical number into a manageable risk factor. It's a reminder that progress in medicine often comes in small, incremental steps, and sometimes the most significant breakthroughs are the ones we almost miss.
